Nanobiotix S.A.
corporate_fare Company Profile
Nanobiotix S.A. (NASDAQ:NBTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for NBTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for NBTX spans 6-K, FWP, 424B5.
Recent high-impact activity:
- Nanobiotix Reports 41.7% ORR and 17.8-Month Median OS in Anti-PD-1-Resistant Melanoma at ESMO
- Nanobiotix H1 2026: Net Loss Widens to €34.3M, Cash at €110.9M After $100M Offering
- Nanobiotix Reports Full Phase 1 Cohort: 79% Locoregional Control, 70% One-Year Survival in Recurrent NSCLC
- Nanobiotix Secures Cash Runway into 2029 with €86.1M Offering Completion
- Nanobiotix Q1 Update: Phase 2 NSCLC Data Shows 57.1% Complete Response, Phase 3 Accelerated, Cash Runway to 2029
Financial Snapshot
Short Interest & Short Volume
1.39 days to coverFINRA reported short interest of 170,082 shares in NBTX as of the October 30, 2026 settlement, a 13.4% decrease from the prior period — about 1.4 days to cover at its recent average daily volume. On November 19, 2026, 27.1% of NBTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NBTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.